Jun 14, 2023
Jun 4, 2023
Nivolumab added to AVD chemotherapy expected to become new standard for initial treatment for advanced stage disease in adolescents and adults, based on trial data to be presented at 2023 ASCO Annual Meeting plenary session
Jun 2, 2023
Changes in RECIST tumor measures correlate linearly with survival in patients treated with checkpoint inhibitors
Jun 2, 2023
Results of SWOG S1929 trial show patients with small-cell lung cancer with SLFN11 expression can benefit from PARP inhibitor added to immune checkpoint blockade
May 31, 2023
S1714 results at ASCO 2023: Taxane-induced peripheral neuropathy in breast cancer: frequent, clinically significant, and worse with paclitaxel
May 30, 2023
SWOG researchers have also contributed to an additional 11 abstracts on studies led by other groups.